The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Repurposing the CRISPR-Cas9 system for targeted DNA methylation
Open accessAbstract
Epigenetic studies relied so far on correlations between epigenetic marks and gene expression pattern. Technologies developed for epigenome editing now enable direct study of functional relevance of precise epigenetic modifications and gene regulation. The reversible nature of epigenetic modifications, including DNA methylation, has been already exploited in cancer therapy for remodeling the aberrant epigenetic landscape. However, this was achieved non-selectively using epigenetic inhibitors. Epigenetic editing at specific loci represents a novel approach that might selectively and heritably alter gene expression. Here, we developed a CRISPR-Cas9-based tool for specific DNA methylation consisting of deactivated Cas9 (dCas9) nuclease and catalytic domain of the DNA methyltransferase DNMT3A targeted by co-expression of a guide RNA to any 20 bp DNA sequence followed by the NGG trinucleotide. We demonstrated targeted CpG methylation in a ∼35 bp wide region by the fusion protein. We also showed that multiple guide RNAs could target the dCas9-DNMT3A construct to multiple adjacent sites, which enabled methylation of a larger part of the promoter. DNA methylation activity was specific for the targeted region and heritable across mitotic divisions. Finally, we demonstrated that directed DNA methylation of a wider promoter region of the target loci IL6ST and BACH2 decreased their expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 3×
“Fluorescence intensities were measured using ImageJ software (41) and percentage of cells expressing Cas9 protein per sample was calculated.”
MethodInfluentialA new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016 · cited 2×
“Even when lower transcript levels were confidently detected after using the inactive construct, they could be explained by CRISPR interference (16), where inactive Cas9 competes with transcription factors for binding to the promoter region.”
Backgroundvan Dongen, J. J. M., Langerak, A. W., Brüggemann, M., Evans, P. A. S., Hummel, M., Lavender, F. L., Delabesse, E., Davi, F., Schuuring, E., García-Sanz, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403202 · Cited by 3,043
Crystal structure of Cas9 in complex with guide RNA and target DNA
Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., & Nureki, O. (2014) · Cell · doi:10.1016/j.cell.2014.02.001 · Cited by 2,306 · cited 1×
“The predicted structure of the fusion product based on the Cas9 crystal structure (42) with the DNMT3A catalytic domain protruding at the PAM–interacting (PI) domain side of Cas9 is depicted in Figure 1A.”
BackgroundGenome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Hilton, I. B., D'Ippolito, A. M., Vockley, C. M., Thakore, P. I., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3199 · Cited by 1,885
RNA-guided gene activation by CRISPR-Cas9-based transcription factors
Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F., Kabadi, A. M., Polstein, L. R., Thakore, P. I., Glass, K. A., Ousterout, D. G., Leong, K. W., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2600 · Cited by 1,328
A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements
Yang, A. S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh032 · Cited by 1,033
Acute Exercise Remodels Promoter Methylation in Human Skeletal Muscle
Barrès, R., Yan, J., Egan, B., Treebak, J. T., Rasmussen, M., Fritz, T., Caidahl, K., Krook, A., O'Gorman, D. J., & Zierath, J. R. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.01.001 · Cited by 965 · cited 1×
“The reversible nature of epigenetic modifications including DNA methylation (17,18) has been already exploited by the use of epigenetic inhibitors (such as inhibitors of DNA methyltransferases or histone deacetylases) in cancer therapy in order to remodel the aberrant epigenetic landscape (19,20).”
BackgroundStructure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation
Jia, D., Jurkowska, R. Z., Zhang, X., Jeltsch, A., & Cheng, X. (2007) · Nature · doi:10.1038/nature06146 · Cited by 846
Optical control of mammalian endogenous transcription and epigenetic states
Konermann, S., Brigham, M. D., Trevino, A. E., Hsu, P. D., Heidenreich, M., Cong, L., Platt, R. J., Scott, D. A., Church, G. M., & Zhang, F. (2013) · Nature · doi:10.1038/nature12466 · Cited by 803 · cited 1×
“Therefore, some of the genome engineering tools have been altered and repurposed for targeted modification of histone tails and the DNA molecule, such as histone methylation (6) and demethylaton (7), histone acetylation (8); cytosine methylation (9–11) and hydroxymethylation (12,13), as well as for direct control of t…”
BackgroundEfficient TALEN-mediated gene knockout in livestock
Carlson, D. F., Tan, W., Lillico, S. G., Stverakova, D., Proudfoot, C., Christian, M., Voytas, D. F., Long, C. R., Whitelaw, C. B. A., & Fahrenkrug, S. C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211446109 · Cited by 580
Maeder, M. L., Angstman, J. F., Richardson, M. E., Linder, S. J., Cascio, V. M., Tsai, S. Q., Ho, Q. H., Sander, J. D., Reyon, D., Bernstein, B. E., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2726 · Cited by 501
A TALEN Genome-Editing System for Generating Human Stem Cell-Based Disease Models
Ding, Q., Lee, Y.-K., Schaefer, E. A. K., Peters, D. T., Veres, A., Kim, K., Kuperwasser, N., Motola, D. L., Meissner, T. B., Hendriks, W. T., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.11.011 · Cited by 501
Dahlem, T. J., Hoshijima, K., Jurynec, M. J., Gunther, D., Starker, C. G., Locke, A. S., Weis, A. M., Voytas, D. F., & Grunwald, D. J. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002861 · Cited by 453
Locus-specific editing of histone modifications at endogenous enhancers
Mendenhall, E. M., Williamson, K. E., Reyon, D., Zou, J. Y., Ram, O., Joung, J. K., & Bernstein, B. E. (2013) · Nature Biotechnology · doi:10.1038/nbt.2701 · Cited by 366
Lauc, G., Huffman, J. E., Pučić, M., Zgaga, L., Adamczyk, B., Mužinić, A., Novokmet, M., Polašek, O., Gornik, O., Krištić, J., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003225 · Cited by 361
Use of Epigenetic Drugs in Disease: An Overview
Heerboth, S., Lapinska, K., Snyder, N., Leary, M., Rollinson, S., & Sarkar, S. (2014) · Genetics & Epigenetics · doi:10.4137/geg.s12270 · Cited by 326
Tsaprouni, L. G., Yang, T.-P., Bell, J., Dick, K. J., Kanoni, S., Nisbet, J., Viñuela, A., Grundberg, E., Nelson, C. P., Meduri, E., et al. (2014) · Epigenetics · doi:10.4161/15592294.2014.969637 · Cited by 319 · cited 1×
“The reversible nature of epigenetic modifications including DNA methylation (17,18) has been already exploited by the use of epigenetic inhibitors (such as inhibitors of DNA methyltransferases or histone deacetylases) in cancer therapy in order to remodel the aberrant epigenetic landscape (19,20).”
BackgroundChen, Z., Mann, J. R., Hsieh, C., Riggs, A. D., & Chédin, F. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20447 · Cited by 230
Epigenetic reprogramming of cancer cells via targeted DNA methylation
Rivenbark, A. G., Stolzenburg, S., Beltran, A. S., Yuan, X., Rots, M. G., Strahl, B. D., & Blancafort, P. (2012) · Epigenetics · doi:10.4161/epi.19507 · Cited by 223
Mechanisms of disease: The human N-glycome
Lauc, G., Pezer, M., Rudan, I., & Campbell, H. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.10.016 · Cited by 184
Valton, J., Dupuy, A., Daboussi, F., Thomas, S., Maréchal, A., Macmaster, R., Melliand, K., Juillerat, A., & Duchateau, P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.408864 · Cited by 180
Siddique, A. N., Nunna, S., Rajavelu, A., Zhang, Y., Jurkowska, R. Z., Reinhardt, R., Rots, M. G., Ragozin, S., Jurkowski, T. P., & Jeltsch, A. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.11.038 · Cited by 172
Inflammatory Bowel Disease Associates with Proinflammatory Potential of the Immunoglobulin G Glycome
Trbojević Akmačić, I., Ventham, N. T., Theodoratou, E., Vučković, F., Kennedy, N. A., Krištić, J., Nimmo, E. R., Kalla, R., Drummond, H., Štambuk, J., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000372 · Cited by 166
Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter
Chen, H., Kazemier, H. G., de Groote, M. L., Ruiters, M. H. J., Xu, G.-L., & Rots, M. G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1019 · Cited by 166
Epigenetic cancer therapy: rationales, targets and drugs
Rius, M., & Lyko, F. (2012) · Oncogene · doi:10.1038/onc.2011.601 · Cited by 157 · cited 1×
“The reversible nature of epigenetic modifications including DNA methylation (17,18) has been already exploited by the use of epigenetic inhibitors (such as inhibitors of DNA methyltransferases or histone deacetylases) in cancer therapy in order to remodel the aberrant epigenetic landscape (19,20).”
BackgroundDoyle, E., Stoddard, B. L., Voytas, D. F., & Bogdanove, A. J. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.04.003 · Cited by 156
GT-Scan: identifying unique genomic targets
O’Brien, A. R., & Bailey, T. L. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu354 · Cited by 152
Li, F., Papworth, M. A., Minczuk, M. A., Rohde, C., Zhang, Y., Ragozin, S., & Jeltsch, A. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl1035 · Cited by 152
TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts
Bernstein, D. L., Lay, J. E. L., Ruano, E. G., & Kaestner, K. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77321 · Cited by 141
Targeted epigenome editing of an endogenous locus with chromatin modifiers is not stably maintained
Kungulovski, G., Nunna, S., Thomas, M., Zanger, U. M., Reinhardt, R., & Jeltsch, A. (2015) · Epigenetics & Chromatin · doi:10.1186/s13072-015-0002-z · Cited by 100
Towards Sustained Silencing of HER2/neu in Cancer By Epigenetic Editing
Falahi, F., Huisman, C., Kazemier, H. G., van der Vlies, P., Kok, K., Hospers, G. A. P., & Rots, M. G. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0567 · Cited by 76
Nunna, S., Reinhardt, R., Ragozin, S., & Jeltsch, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087703 · Cited by 73
Epigenetic regulation of glycosylation is the quantum mechanics of biology.
Lauc, G., Vojta, A., & Zoldoš, V. (2014) · Biochimica et Biophysica Acta · doi:10.1016/j.bbagen.2013.08.017 · Cited by 70
Self-citationCpG Sites Preferentially Methylated by Dnmt3a in Vivo
Oka, M., Rodić, N., Graddy, J., Chang, L., & Terada, N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511100200 · Cited by 62
Strauβ, A., & Lahaye, T. (2013) · Molecular Plant · doi:10.1093/mp/sst075 · Cited by 47
Epigenetic silencing ofHNF1Aassociates with changes in the composition of the human plasmaN-glycome
Zoldoš, V., Horvat, T., Novokmet, M., Cuenin, C., Mužinić, A., Pučić‐Baković, M., Huffman, J. E., Gornik, O., Polašek, O., Campbell, H., et al. (2012) · Epigenetics · doi:10.4161/epi.7.2.18918 · Cited by 45
Self-citation
Cited by
The diverse roles of DNA methylation in mammalian development and disease
Greenberg, M. V. C., & Bourc’his, D. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0159-6 · Cited by 2,161
The CRISPR tool kit for genome editing and beyond
Adli, M. (2018) · Nature Communications · doi:10.1038/s41467-018-04252-2 · Cited by 1,545
The DNA methyltransferase family: a versatile toolkit for epigenetic regulation
Lyko, F. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.80 · Cited by 1,467
Editing DNA Methylation in the Mammalian Genome
Liu, X. S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R. A., & Jaenisch, R. (2016) · Cell · doi:10.1016/j.cell.2016.08.056 · Cited by 1,224
“also reported that dCas9 fused with Dnmt3a can be used to methylate two human gene promoters (Vojta et al., 2016), and Xu et al.”
Horlbeck, M. A., Gilbert, L. A., Villalta, J. E., Adamson, B., Pak, R. A., Chen, Y., Fields, A. P., Park, C. Y., Corn, J. E., Kampmann, M., et al. (2016) · eLife · doi:10.7554/elife.19760 · Cited by 894
Metadata
- Authors
- Vojta, A., Dobrinić, P., Tadić, V., Bočkor, L., Korać, P., Julg, B., Klasić, M., & Zoldoš, V.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-03-11
- Volume
- 44
- Issue
- 12
- Pages
- 5615-5628
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2294327742
- Cited by
- 777
- References
- 43
- FWCI
- 48.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.